%0 Case Reports
%T [Shrinking lung syndrome in systemic lupus erythematosus: A study of 9 patients].
%A Casey A
%A Enghelmayer JI
%A Legarreta CG
%A Berón AM
%A Perín MM
%A Dubinsky D
%J Med Clin (Barc)
%V 162
%N 7
%D 2024 04 12
%M 38195280
%F 3.2
%R 10.1016/j.medcli.2023.10.023
%X Shrinking lung syndrome (SLS) is a rare manifestation of systemic lupus erythematosus. Our aim was to describe the clinical, radiological, and functional characteristics of a cohort with SLS and its evolution over time.<BR>A retrospective study was conducted between 2009 and 2018. Demographic, clinical, functional, radiological, and treatment data were collected.<BR>Out of a total of 225 patients, 11 presented with SLS (prevalence of 4.8%). Two patients were excluded. The mean age was 39.33±16 years, and 6 were female. The main symptoms were dyspnea and pleuritic pain. The mean forced vital capacity was 49%, total lung capacity was 60%, carbon monoxide diffusing capacity was 66%, carbon monoxide transference factor was 128%, maximal inspiratory pressure was 66%, and maximal expiratory pressure was 82%. All patients received corticosteroids. After a median follow-up of 19 months, 4 cases showed improvement, and 4 cases remained stable.<BR>SLS should be considered in every lupus patient with unexplained dyspnea. Although it often shows improvement, many cases experience persistent deterioration despite treatment.